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Abstract
Background: Gout is the most common form of inflammatory arthritis. It is associated with substantial co-morbidity
and often managed in primary care. A greater understanding of the communication process between patients and
healthcare professionals provides one way of improving the management of this condition. This paper describes
communication about gout medicines and treatment between patients and primary care health professionals during
routine consultations.
Methods: Video-recordings of 31 individual healthcare consultations between patients and a range of primary care
practitioners (general practitioners, practice nurses, podiatrists, dietitians) from an archived database were reviewed.
Consultations that encompassed any discussion about gout medicines and treatment were included (n = 27) and
were not solely restricted to those where gout was the presenting complaint. Themes were derived from an inductive
qualitative analysis, from clinical and linguistic perspectives, based on the conversation between patients and
practitioners about medicines and visual observation of these interactions.
Results: A number of factors were identified that had the potential to impact on the optimal management
of gout in primary care. These included level of patient knowledge, patient attitudes to medicines, and the
attributes of practitioner communication with patients. The latter related to the style of delivery and content
of the information provided, and the ability of practitioners to make use of opportunities that arose to discuss these
issues.
Conclusions: Patients with gout communicate at varying levels of complexity with a diverse range of primary care
healthcare professionals about the treatment of their condition. It is important that all practitioners engaging with
gout patients in this setting are knowledgeable about the current management of gout, provide clear, consistent and
accurate messages, remain aware that these messages may need repeating over time, and are supportive of patients’
medicine-taking preferences.
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Background
Gout is recognised as the most common form of inflam-
matory arthritis and is often associated with substantial
co-morbidity [1]. This condition, usually managed in
primary care, is closely linked with diabetes and chronic
kidney disease and is an independent risk factor for
cardiovascular mortality [2]. The clinical and economic
burden of the disease is substantial [3, 4].
Some aspects of gout management appear straightfor-
ward and there is a plethora of management reviews and
treatment guidelines in existence globally [1, 5–9]. Non-
steroidal anti-inflammatory drugs (NSAIDs) are one of
the main medicine groups used for the management of
acute flares, with colchicine and steroids providing alter-
native treatment options. A target serum uric acid level
of less than 0.36 mmol/L is aimed for and allopurinol
and other urate-lowering therapies are indicated for the
chronic management of gout.
The burden of the disease is rising, [3] and aspects of
management remain challenging. Differences in primary
care management strategies have been widely noted be-
tween routine practice and both reported management
and recommended guidelines [10–15].
Differing patient and physician perceptions of gout
have been identified as one of the challenges to manage-
ment in primary care [16]. Issues identified include
patients experiencing difficulty in obtaining information
they perceive as directly relevant to them, [17] self-
diagnosis and treatment by patients, [18] a lack of
patient knowledge about gout medicines, [19–22] a
lack of practitioner knowledge about treatment guide-
lines and recommendations [21] and a reluctance on
the part of some practitioners to offer preventive
medicines as a long-term solution, with some making
an assumption that patients would prefer to be
treated for an acute flare rather than take long-term
medication [21].
While some previous studies have attempted to ad-
dress views about gout treatment from both patient and
practitioner perspectives, [21, 23] there is no research
that investigates directly observed conversations in pri-
mary care consultations. Existing findings therefore rely
on people’s abstract perceptions or retrospective reports
of healthcare encounters. We describe communication
between patients and primary care practitioners about
gout medicines and treatment in the context of routine
consultations. We identify how patient and practitioner
perceptions are brought into play in the course of nat-
ural interactions between them. The prevalence of gout,
due to its association with cardio-vascular disease and
diabetes, is likely to increase further. A greater under-
standing of the communication process will help




Data were derived from the Applied Research on Com-
munication in Health (ARCH) Corpus at the University
of Otago, Wellington, New Zealand [24]. This comprises
a searchable digital collection of healthcare interactions
and related data for use in interactional and narrative
analysis. The data in the Corpus has been collected in
the course of a series of funded projects since 2003.
These studies include the ‘Interaction Study’ (IS), a study
exploring clinical decision-making when rationing is
explicit; the Tracking Study (TS), a study exploring com-
munication processes throughout a single complete
episode of care of patients referred from primary to sec-
ondary care; the Diabetes Study (DS), a longitudinal
study tracking the contact of newly diagnosed patients
with Type 2 diabetes with healthcare professionals over
a six-month period. Data are permanently archived for
use by authorised researchers.
As the data contained in the Corpus has been col-
lected on a project-by-project basis it does not claim to
be ‘representative’ in the statistical sense. It is, however,
representative in the sense that the video-recordings
were made in the course of ‘practice as usual’. They are
therefore typical of routine interactions occurring in the
New Zealand healthcare setting.
Logging of data in the ARCH Corpus
The digital video-recording for each consultation is
logged by a trained research nurse onto a template sum-
marising key clinical content (e.g. presenting problem,
other clinical issues discussed, treatment with medicines)
and a time-coded sequence of key events and topics dis-
cussed. Each consultation is subsequently transcribed in
full using linguistic transcription conventions to capture
both the words spoken and selected non-verbal cues
(e.g. typing of notes on the computer) to assist in inter-
pretation of the transcribed speech. The Corpus has a
custom-designed information management system.
Search strategy for identifying gout consultations
When sampled, the Corpus included 418 video-recorded
interactions between patients and practitioners recorded
between 2004 and 2011. Consultations occurring in pri-
mary care and consultations where patients had given
consent for secondary analysis of their data were in-
cluded, resulting in a subset of 337 eligible consultations.
These comprised 247 individual patients, 30 general
practitioners (GPs), 31 nurses and 15 other practitioners.
A query was then run on the information held within
the database using the keyword “gout”. A second search
incorporating a list of key gout-related medicines was
run, but did not yield any additional consultations.
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Consultations included in the analysis
The search identified 31 consultations, 27 of which were
included in the final analysis.
The majority of consultations identified came from
those archived as part of the DS (n = 20). Gout was not,
therefore, the primary focus of these encounters; many
gout-related conversations stemmed from enquiries
made by practitioners that resulted directly from appli-
cation of the nationally agreed protocol for diabetes care.
Despite this, discussion about gout medicines of varying
length and complexity was a feature in the majority of
these consultations (n = 16). In the remaining four, there
was no mention of medicines in the context of gout;
these consultations were therefore excluded from further
analysis. As this study tracked patients over a six-month
time-frame, the same patient was sometimes involved in
more than one consultation in the sample and poten-
tially more likely to discuss gout medicines with a practi-
tioner if they had talked about them in a healthcare
encounter in the recent past.
Contextual information about the 11 GP consulta-
tions derived from the IS study (n = 5) and the TS
study (n = 6) is provided in Table 1.
Patient and practitioner demographic characteristics
The final dataset of 27 consultations used for analysis
encompassed 17 individual patients (male n = 12, female
n = 5; age-range 36 to 67 years) consulting with 15 differ-
ent practitioners. The number of consultations per patient
ranged from one to eight, with the majority of patients
(14/17) having only one included consultation. Patients
interacted with a diverse range of professionals (GPs n = 9,
nurses n = 3, podiatrists n = 2, dietitian n = 1).
Data analysis
This was an exploratory descriptive study based on direct
observation of gout-related interactions from both clinical
and linguistic viewpoints. Our aim was to identify and re-
port on the range of patient-practitioner models of en-
gagement around medicines use as these emerged from
the data, with no preconceived assumptions.
Themes identified from the overall dataset were de-
rived via an iterative process of inductive qualitative ana-
lysis [25] of the medicine-related gout conversations
between patients and practitioners, with visual observa-
tion of these interactions complementing the textual
analysis of the transcripts. CM identified and coded all
mentions or sequences of talk relating to the use of
medicines in the management of gout in the transcripts.
Video-recordings of consultations were then viewed to
confirm and enrich the content analysis of the tran-
scripts. Initial coding included the location within the
consultation, who (patient or practitioner) initiated the
conversation, the types and names of medicines dis-
cussed, the context in which that discussion took place
and any significant non-verbal interactions. The video-
recordings and transcripts were then re-reviewed to
identify any other medicine-related conversation to help
provide additional insights and context for the gout-
related medicines communication. CM and AD reviewed
and discussed the initial themes derived from data ana-
lysis and interpretation of data from their clinical
perspectives (pharmacy and general practice), with dis-
agreements resolved by consensus. LM and MS subse-
quently reviewed the data and themes derived from a
linguistic and interactional perspective. All authors
reviewed and agreed the final themes.
Results
Communication about gout medicines
Interactions about gout treatment occurred at various
levels of complexity, taking many different forms. Some
focused solely on the treatment of acute flares with
NSAIDs, colchicine or steroid injections, some solely on
preventive treatment with allopurinol, while others
encompassed both acute and chronic management.
Three overarching themes emerged from our data.
These themes (and sub-themes where applicable) are
shown in Table 2 and described more fully below. Abbre-
viations used in the quotes are as follows: GP = general
practitioner; NS = nurse; PT = patient; POD = podiatrist.
Level of patient knowledge
We identified a number of instances where patients dis-
played a lack of important knowledge about medicines
used for gout. NSAIDs, a medicine class with significant
potential to cause harm if inappropriately used, caused
confusion for a number of patients. In this example a
patient with a long-standing diagnosis of gout had been
unsuccessfully self-treating an acute flare with an insuffi-
cient dose of a medicine purchased over-the-counter:
Table 1 GP consultations that were not part of the DS (n = 11)
Description Number
Gout was the patient’s presenting complaint 2
Gout was the presenting complaint in the patient’s
previous consultation (not part of the Corpus archive)
and was followed up by the GP on this occasion
2
Gout discussed in the context of a medicine that had
been previously prescribed for this condition
7
GP general practitioner
Table 2 Overarching themes and sub-themes identified from
the data
• Level of patient knowledge
• Patient attitudes to medicines
• Attributes of practitioner communication
- Delivery and content of information provided
- Taking the opportunities presented
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GP: so, you’d been taking lots of … those ‘mini’
Voltarens™ [diclofenac 25 mg strength], and so we
switched you on to the one hundreds [100 mg
strength] ... and when you started on those initially
you said there was a bit of improvement …” (IS-
GP02-14)
The GP then listens carefully and attentively to the
patient as they describe the beneficial effect that this
increase in dose has had on their symptoms over
time.
In addition, some patients showed a lack of under-
standing of generic and brand (™) names, not realising
that the same medicine could have two different names.
In this consultation, a patient with a history of hip pain
managed with an NSAID is newly diagnosed with gout.
The GP spends considerable time explaining the causes
and symptoms of gout before mentioning treatment with
medicines:
GP: “… I’ll give you some diclofenac, … it’s good for
your gout and also for the other pain
PT: and can I have some Voltaren™ [diclofenac]
please?
GP: It’s the same thing as Voltaren™ [diclofenac]
PT: Is it?” (DS-GP29-01)
The following patient with a confirmed diagnosis of
gout is already willingly taking a low dose of allopurinol
as preventive therapy. However, this is not currently ad-
equately managing their symptoms. The GP explains the
reason why they are unable at this point to increase the
dose:
Joint consultation with nurse and GP:
GP: “… now you know those allopurinol tablets for
the gout, you still taking them?
PT: yep, cos I wanted to prevent the gout
GP: the problem [is] that’s quite a low dose and we
probably need to increase it, but I can’t increase it
when you’ve got acute gout because it gets worse
so … what we’ll do is leave you on that dose and
increase it in a couple of weeks when it’s better.”
(DS-NS13-01c_GP18)
The patient smiles indicating that they are comfortable
with this approach and understanding of the reasoning
behind it. The following excerpts from subsequent con-
sultations with this patient and other practitioners
appear to show that a patient’s understanding may
evolve over time and that confusion may creep in as a
result.
Consultation with dietitian two weeks later:
PT: “They haven’t put me on [more] of the
medication [allopurinol] because this can enhance
more gout, so they just said to me to stick on what
I’ve got and hopefully when I get rid of the gout
they’ll increase it, so it can lower the [number of]
times I have gout.” (DS-HP06-01b)
The patient had been given information by one practi-
tioner (GP) and then recited that same information back
to another practitioner (dietitian) a short time later. Two
weeks after this, the patient recalls that they were to stay
on the same dose, and reconsiders their situation in light
of their worsening symptoms. While doing so they are
also now questioning the possibility that allopurinol can
exacerbate gout.
Consultation with podiatrist one month after the GP
consultation:
PT: “It [gout] started from my toes round to my ankle
and then it just stayed there for a while and it just
slowly headed up … [and] they told me to keep on it
[allopurinol] … so I stayed on that and I thought that
was triggering it because that’s the longest I’ve ever
had gout … [and] I wasn’t quite sure … and I was
questioning myself ‘Should I stop it?’ cos I don’t know
if that was triggering it worse
POD: but it’s a treatment for gout so you wouldn’t
think it would actually exacerbate your symptoms or
pain …” (DS-HP07-01b)
This consultation series also shows that in primary
care teams with multiple healthcare professionals, advice
about medicines may be given by professionals other
than the prescriber. In this instance it would have been
helpful if the podiatrist could have appropriately ad-
dressed the patient’s understanding. However, in the
final quotation, the podiatrist seems unaware of the
action of allopurinol and inadvertently creates a further
source of confusion potentially undermining the patient’s
knowledge and understanding of gout treatment.
Patient attitudes to medicines
It was clear that how patients perceived medicines
sometimes impacted on the way in which their gout was
treated. One patient with previously diagnosed gout
identified “I don’t like tablets” as a general statement at
the beginning of a consultation and then segued straight
into talking specifically about gout:
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PT: “… and I said before, I told you with my gout I
don’t want to take any more tablets …
GP: When did you last have a flare of gout?
PT: Well, sometimes I feel it is a little bit sore on my
elbow but I don’t take anything - it comes and goes …
GP: “… your uric acid level in your blood, that’s the
one that’s associated with gout is still high, so I think
if you do start having regular flare-ups then we should
look again at putting you back on allopurinol to bring
that uric acid level down.” (DS-GP19-02b)
While it was unclear what the patient’s uric acid level
was or whether allopurinol therapy at this point was jus-
tified, clinically, the impact of the condition on the
patient’s life appeared manageable without the use of
medicines. It is possible that the GP may have judged
the level of clinical severity against the patient’s desire to
be tablet-free and they appeared accepting of the
patient’s preference at this point in time. While there
was no discussion about the reasons for the patient’s
reticence to take medicines, the possible future need for
treatment with tablets was brought clearly into the open
by the GP, with tacit approval from the patient indicated
by a nodding of their head and a verbal acknowledgment
in the form of “yeah, yeah”.
Another patient was fully aware of the potential
adverse impact that taking an NSAID for her long-
term gout symptoms could have on a co-morbid
condition. Although her specific circumstances dic-
tated that she took the medicine anyway, she had
developed a personal strategy in an attempt to min-
imise the risk:
NS: “What are you taking in terms of pain relief?
PT: Well, I actually ran out of what [the GP] gave
me … and all I had was diclofenac … so what I
was trying to do was half it [the dose] because I
was in so much pain because I know that the
diclofenac triggers my asthma” (DS-NS13-
01d_GP18)
There is no discussion or negotiation about alternative
options that may be more suitable for the patient, nor is
the patient able to glean what the nurse may think by ei-
ther verbal or non-verbal means. The consultation
moves swiftly on to codeine, another medicine that the
patient is taking for pain relief, and its tendency to cause
constipation:
PT: “so then I had, what do you call it, codeine
NS: codeine doesn’t help the constipation either”
(DS-NS13-01d_GP18)
Attributes of practitioner communication
Delivery and content of information provided
Communication style varied across the consultations.
Many practitioners asked open questions, clearly listened
to the patient’s view, provided clear, accurate informa-
tion, and confirmed that the patient understood this in-
formation and was comfortable with the final decision.
In this example the patient presented to the GP because
they had run out medicines. This prompts a general dis-
cussion about their medicines leading to the patient
describing symptoms they knew to be gout:
GP: “… getting a good dose of diclofenac would be
probably the most useful thing; so this is your first
gout attack for a long, long time isn’t it? So I don’t
think we need to look at the allopurinol thing
PT: well, no cos I mean this attack, I totally knew
[the cause], it just didn’t occur to me at the time,
it was just silly, but yeah this [attack] isn’t a
mystery” (TS-GP09-05)
There was clear agreement between them, with the GP
smiling and both parties verbally acknowledging that they
were happy with this approach by saying “mm mm”.
In another consultation a substantial amount of dis-
cussion, initially raised by the GP, took place around the
use of colchicine in a patient with gout that had previ-
ously proven difficult to manage. Effective clear commu-
nication with the patient occurred resulting in a clear
management plan agreed by both parties. The only con-
tentious issue here might be the use of the word
“prophylaxis”; something that may not necessarily be
understood by the patient:
GP: “… allopurinol is probably an option, but [the
specialist] thought you should stay on colchicine …
which is what you’ve done isn’t it? One tablet twice a
day for the prophylaxis and I think if that’s doing the
trick and not giving you symptoms then that’s fine …
if that turned [out] for any reason not to be suiting
you in terms of prevention; either not effective
enough or giving you side effects, then there are the
other things that we can try
PT: I’m actually only taking one a day, it seems to be
effective so then I guess I could
GP: if one a day is doing it that’s fine [but] you can
easily up it to two if you’re getting any breakthrough -
it would be fine.” (IS-GP02-03)
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The patient tacitly indicates by nodding his head that
he agrees with the GP.
All of the podiatrist consultations (n = 4) were with
patients with diabetes and featured practitioner engage-
ment with the patient around medicines to some degree.
These consultations were relatively lengthy (between 20
and 30 min) compared to GP consultations and talk
about medicines was usually used as a time-filler follow-
ing what seemed to be uncomfortably long gaps of
silence for the practitioner. The following extract took
place 10 min into a consultation where the podiatrist
had been asking questions or providing information
about diabetes with limited response from the patient:
POD: “… [gout] that’s a type of arthritis [that] tends
to run in families … it can be quite painful gout are
you on medication for it?
PT: Yes” (DS-HP10-02a)
Taking the opportunities presented
While a small number of ‘lost’ opportunities to discuss
gout and gout medicines were identified across the data-
set, there were many excellent examples of practitioners
making good use of opportunities that presented them-
selves by responding to ‘openings’ provided by patients.
In this example the patient raises the issue of gout,
identifying that he had been given an unnamed “inject-
able treatment” abroad in the past. Although the patient
clearly articulates that gout is not currently a problem,
the GP seamlessly picks up on the opportunity to ex-
plain the rationale for his current treatment approach
offering reassurance that alternative options exist should
the patient’s circumstances change:
PT: “…I do get gout … but it normally goes away by
itself. I think the last time would have been last year
sometime …
GP: I feel we’ve got more than enough information
right now to know what the next step should be and
at this stage, because things are not that bad, I’m
saying I’d quite like to be very conservative in this and
not push you know lots and lots of treatment, but
we’ve got it there waiting if things got a bit [clinically]
worse or didn’t improve as far as these [uric acid]
numbers are concerned” (DS-GP01-04)
The patient listens carefully to the explanation, smiles,
maintains eye contact and nods their head in acceptance.
Another example shows the potential benefit of coor-
dinated multidisciplinary care. This patient had
expressed concern about their gout pain to the nurse in
an appointment the previous week. The nurse then
reintroduces this issue in their second consultation, dis-
cussing the patient’s symptoms with them and identify-
ing that there was a need to involve the GP further in
their gout-related care. In this instance, having been pro-
vided with information about a new treatment option
for their symptoms the patient very clearly verbally artic-
ulates that this is something they would like to try.
NS: “I had a wee chat with [GP’s name] … you had a
concern about your toes about the gout … and she
says that if you’re having more than two episodes in a
year
PT: oh yes definitely
NS: oh okay, she said then you probably need some
treatment which you carry on taking long-term be-
cause it helps to prevent [gout]
PT: oh I would - it’s always at the back of my ankle
and … it gets right here [pointing at foot] and I can’t
walk on it and stuff like that, six times maybe seven
times a year easily and they all swell up and the other
place I get it is on my side of my toes …
NS: have you got those symptoms at the moment? No
okay, alright so I probably need to leave a message for
[the GP]” (DS-NS13-01b)
However, not all patient-practitioner gout interactions
resulted in any significant discussion about the condi-
tion. Sometimes another potentially more pressing prob-
lem or patient concern becomes the focus of that part of
the consultation and the moment and the potential op-
portunity has passed.
Only one example of an opportunity being truly
missed was identified from the dataset. This practitioner
phrased her question about a gout medicine in a closed
way that did not invite debate or discussion as she sim-
ultaneously turns her back to the patient and prints out
a computer generated blood test form:
NS: “your allopurinol, you know about it don’t you?
It’s the same. So that’s a fasting blood test [form], first
thing in the morning for fasting …” (DS-NS27-02)
There is silence while the form is printing and once
this is done the nurse hands it to the patient, explains
what fasting means, advises them when they should
schedule their next visit and the consultation is closed.
Discussion
Our study is the first to describe communication about
medicines for gout treatment in the context of routine
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consultations in primary care. We identified three over-
arching themes from the data; level of patient knowledge
about gout medicines, patients’ attitudes towards medi-
cines, and the attributes of practitioner communication.
Each of these inter-linking themes has the potential to
impact either positively or adversely on the successful
management of gout. Optimising the manner, and ave-
nues, by which information is shared with patients has the
potential to improve patient knowledge and understand-
ing, and promote clinician-patient agreement. A link be-
tween good communication and positive health outcomes
has been previously described in the literature [26].
The strength of our study is that it enabled us to see,
hear and review the interaction between patients and
their practitioner in real encounters, rather than relying
on the abstract views or retrospective opinions of each
party. As some of the included consultations formed
part of a longitudinal study we were also able to review
encounters with a range of practitioners and gain insight
into how patients’ knowledge and attitudes may alter
over time. Although data were drawn from an archived
database rather than a study specifically related to gout,
the use of a video-recorder may have introduced an arti-
ficial bias, with participants behaving differently from
‘normal’ due to its presence. However, although all par-
ties appear cognisant of a camera’s presence early on in
a consultation, this effect can be observed to wane as
the business of the consultation progresses [27].
It was concerning that some patients lacked basic
knowledge about the main medicines used for gout
treatment. This has clear implications for the quality
and safety of medicines use. In line with earlier work,
[19, 20] this study revealed lack of knowledge related to
the appropriate NSAID dosing for an acute gout flare
and confusion around NSAID generic and brand names.
Some patients also lacked a clear understanding of the
specific and unusual issues around the initiation of allo-
purinol therapy; an area which has been previously iden-
tified as a source of patient confusion [19, 20, 28].
It was evident on following a single patient through a
series of consultations that information may need re-
peated explanation to ensure that understanding remains
consistent over time. Information that appeared to be
unproblematic when initially given became less clearly
understood by the patient as time progressed and other
experiences intervened. All healthcare professionals that
may interact with patients, including community phar-
macists, have a potentially valuable role to play in facili-
tating patient understanding and hence the safe and
effective use of medicines.
The level of knowledge about gout treatment may im-
pinge on patients’ attitudes towards gout medicines and
the likelihood of patient-practitioner concordance [29].
There were examples in the present study of patients
taking medicines ‘differently’ to the way the practitioner
expected and a reticence expressed, by some, to taking
preventive medicines long-term. To be considered for
preventive treatment patients will have been previously
symptomatic, although the level of pain experienced by
an individual may vary widely. It is therefore not surpris-
ing that here, and in previous studies, [19, 23] patients
have admitted to failing to take medicines both uninten-
tionally (they were unaware of how it should be taken or
simply forgot) and intentionally (they had no desire to
take a medicine every day) [19, 23]. It is notable that one
patient continued to take a medicine to treat gout des-
pite the fact that it exacerbated a co-morbid condition,
identifying that patient values and judgments around
medicine side-effects may differ from their practitioner’s.
Communicating in an open way and engaging the
patient in a discussion about treatment options is likely
to increase patient knowledge about the rationale behind
their treatment and potentially promote agreement and
adherence to a treatment plan that takes account of the
patient’s beliefs and wishes [29]. Although some patients
may ultimately choose to defer a treatment decision to
their healthcare professional, the majority desire some
level of involvement in the decision-making process
[30]. Patients are only able to make an informed and
evaluated decision on how they personally wish to en-
gage with medicine taking or sign-up to a suggested
treatment plan if they have appropriate and accurate in-
formation on which to base their decision. It is therefore
of note that gout patients have previously identified that
they did not always understand the information that GPs
provided and have suggested that practitioners should
explicitly confirm their understanding [19]. Furthermore,
as in our study, potentially important mismatches in
perceptions between patients and healthcare providers
(including doctors, nurses, podiatrists) about the effect-
iveness and place of specific medicines in gout manage-
ment and the adequacy of information provided have
been shown to exist [23].
The present study reviewed consultations with a range
of different primary care health professionals. It was not-
able that medicines were a feature of consultations
across all professional groups, although, not surprisingly,
medicines-related talk occurred to a greater extent with
GPs who are the prescriber of medicines. It is, however,
vital that all practitioners engaging with gout patients
are knowledgeable about the up-to-date management of
this condition and provide clear, consistent and accurate
messages to avoid the potential for misleading or confus-
ing patients.
While our findings potentially have relevance to other
musculoskeletal conditions, it is possible that communica-
tion between patients and practitioners about gout treat-
ment may differ from, for example, osteoarthritis [31]. In
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contrast to this condition, gout can be effectively managed
using preventive therapy and is far less likely to be per-
ceived as a normal part of getting old.
Our study was undertaken in the context of routine
clinical practice. It thus allowed us to view the commu-
nication process within the real time constraints under
which practitioners undertake their daily work. Further-
more, consultations were not solely for gout providing,
for the first time, an indication of how this issue is rou-
tinely raised in primary care practice. Overall, there were
many examples of good communication; practitioners
often use open questions, are supportive of their pa-
tients’ medicines-related preferences and seize oppor-
tunities that present to discuss gout and its treatment.
The difficulty of managing patients with gout and its
associated co-morbidities in a short consultation is a key
challenge to the optimal management of gout in primary
care [16]. Given that medicines are a key feature of gout
management and that GP consultation time con-
straints are unlikely to be easily overcome, a multidis-
ciplinary team approach to care via primary care gout
clinics including pharmacist input has been recently
reported [32].
Conclusions
Patients with gout communicate at varying levels of
complexity with a range of primary care practitioners.
All practitioners who interact with gout patients need to
be able to provide patients with clear, consistent and
accurate messages about gout treatment as the need
arises, be aware that these messages may need repeating
over time, and be supportive of patients’ medicine-
taking preferences for this condition.
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